抗蛋白C抗体与获得性蛋白C抵抗:SLE血栓事件与疾病活动的新标志物?
横断面研究纳入156例SLE患者,检测IgG抗蛋白C抗体及其亲和力,并用凝血酶生成试验评估对外源性rhAPC和内源性蛋白C激活剂Protac的APCR。结果显示抗蛋白C抗体与APCR相关,高亲和力抗蛋白C抗体与血栓形成及疾病活动相关。
要点
- SLE患者中抗蛋白C抗体检出率54.5%,APCR检出率59%,两者显著相关。
- 高亲和力抗蛋白C抗体(26.3%)与血栓形成及疾病活动(SLEDAI-2K、BILAG)相关。
- 抗蛋白C抗体独立于aPL谱出现,可能成为监测SLE血栓风险的新标志物。
核心结论
- 抗蛋白C抗体在SLE患者中独立于aPL谱出现,并与APCR相关。
- 高亲和力抗蛋白C抗体与血栓形成及疾病活动相关,可能成为监测血栓风险和疾病进展的新标志物。
研究设计与样本
- 横断面研究,纳入156例SLE患者。
- 用in house-ELISA检测IgG抗蛋白C抗体的存在和亲和力,用凝血酶生成试验评估对外源性rhAPC和Protac的APCR。
- 分析抗蛋白C抗体与aPL谱、血栓史及疾病活动(BILAG和SLEDAI-2K)的关联。
主要发现
- 抗蛋白C抗体检出率为54.5%,APCR检出率为59%。
- 抗蛋白C抗体阳性与对rhAPC的APCR相关(P <0.0001),也与对Protac的APCR相关(P =0.0001)。
- 高亲和力抗蛋白C抗体检出率为26.3%,仅在血栓形成患者中与APCR相关(P <0.05),并与随时间发生血栓形成相关(范围:0-52年;P =0.014)。
- 高亲和力抗蛋白C抗体水平与SLEDAI-2K相关(P =0.033),与总BILAG相关(P =0.019);SLEDAI-2K与对Protac的APCR呈负相关(P =0.004)。
关键数值与推荐
- 抗蛋白C抗体检出率54.5%,APCR检出率59%,高亲和力抗蛋白C抗体检出率26.3%。
- 抗蛋白C抗体阳性与对rhAPC的APCR相关(P <0.0001),与对Protac的APCR相关(P =0.0001)。
- 高亲和力抗蛋白C抗体仅在血栓形成患者中与APCR相关(P <0.05),与随时间发生血栓形成相关(范围:0-52年;P =0.014)。
- 高亲和力抗蛋白C抗体水平与SLEDAI-2K相关(P =0.033),与总BILAG相关(P =0.019);SLEDAI-2K与对Protac的APCR呈负相关(P =0.004)。
临床怎么用
- 在SLE患者中可考虑检测抗蛋白C抗体及其亲和力,辅助评估血栓风险。
- 高亲和力抗蛋白C抗体可能作为监测SLE疾病活动和血栓事件的潜在标志物。
局限性
- 横断面设计无法确定因果关系。
- 样本量有限(156例SLE患者),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Risk factors for thromboembolism in SLE are poorly understood. We hypothesized a possible role for protein C, based on its dual activity in inflammation and haemostasis and on the evidence of an association between acquired activated protein C (APC) resistance (APCR) and high-avidity anti-protein C antibodies (anti-PC) with a severe thrombotic phenotype in venous thrombosis APS patients. METHODS: In a cross-sectional study of 156 SLE patients, the presence and avidity of IgG anti-PC was established by in house-ELISA, and APCR to exogenous recombinant human APC (rhAPC) and Protac (which activates endogenous protein C) was assessed by thrombin generation-based assays. Associations with aPL profile, thrombotic history and disease activity (BILAG and SLEDAI-2K) were also established. RESULTS: Anti-PC were detected in 54.5% of patients and APCR in 59%. Anti-PC positivity was associated with APCR to both rhAPC (P <0.0001) and Protac (P =0.0001). High-avidity anti-PC, detected in 26.3% of SLE patients, were associated with APCR in patients with thrombosis only (P <0.05), and with the development of thrombosis over time (range: 0-52 years; P =0.014). High-avidity anti-PC levels correlated with SLEDAI-2K (P =0.033) and total BILAG (P =0.019); SLEDAI-2K correlated inversely with APCR to Protac (P =0.004). CONCLUSION: Anti-PC occur in patients with SLE, independently of aPL profile, and are associated with APCR. High-avidity anti-PC are associated with thrombosis and with active disease and might prove a novel marker to monitor the risk of thrombosis and disease progression in SLE.
引用
- Ramirez GA, Mackie I, Nallamilli S, et al. Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity? Rheumatology (Oxford). 2021. PMID: 32964932. doi:10.1093/rheumatology/keaa509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。